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Abstract: Myotonic Dystrophy type 1 (DM1) is a multi-system disorder characterized by muscle wasting, myotonia, car-
diac conduction defects, cataracts, and neuropsychological dysfunction. DM1 is caused by expansion of a CTG repeat in 
the 3´untranslated region (UTR) of the Dystrophia Myotonica Protein Kinase (DMPK) gene. A body of work demon-
strates that DMPK mRNAs containing abnormally expanded CUG repeats are toxic to several cell types. A core mecha-
nism underlying symptoms of DM1 is that mutant DMPK RNA interferes with the developmentally regulated alternative 
splicing of defined pre-mRNAs. Expanded CUG repeats fold into ds(CUG) hairpins that sequester nuclear proteins in-
cluding human Muscleblind-like (MBNL) and hnRNP H alternative splicing factors. DM1 cells activate CELF family 
member CUG-BP1 protein through hyperphosphorylation and stabilization in the cell nucleus. CUG-BP1 and MBNL1 
proteins act antagonistically in exon selection in several pre-mRNA transcripts, thus MBNL1 sequestration and increase 
in nuclear activity of CUG-BP1 both act synergistically to missplice defined transcripts. Mutant DMPK-mediated effect 
on subcellular localization, and defective phosphorylation of cytoplasmic CUG-BP1, have additionally been linked to de-
fective translation of p21 and MEF2A in DM1, possibly explaining delayed differentiation of DM1 muscle cells. Mutant 
DMPK transcripts bind and sequester transcription factors such as Specificity protein 1 leading to reduced transcription of 
selected genes. Recently, transcripts containing long hairpin structures of CUG repeats have been shown to be a Dicer ri-
bonuclease target and Dicer-induced downregulation of the mutant DMPK transcripts triggers silencing effects on RNAs 
containing long complementary repeats. In summary, mutant DMPK transcripts alter gene transcription, alternative splic-
ing, and translation of specific gene transcripts, and have the ability to trigger gene-specific silencing effects in DM1 cells. 
Therapies aimed at reversing these gene expression alterations should prove effective ways to treat DM1.  
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INTRODUCTION  
  Myotonic Dystrophy type 1 (DM1; OMIM 160900) is a 
particularly complex inherited disease both from the clinical 
and the genetic standpoints. Clinically, it affects up to 11 
organ systems including the muscular, nervous, ocular, di-
gestive, respiratory and cardiovascular systems. Characteris-
tic disabilities are loss of muscle strength, with a distal to 
proximal pattern, myotonia, excessive daytime sleepiness, 
excessive fatigue, abdominal pain as well as dysphagia [1, 
2]. Although rare, it is estimated that the worldwide preva-
lence ranges between 2.1 and 14.3 per 100,000 [3, 4], being 
the most common form of muscular dystrophy in adults. Ge-
netically, DM1 involves a CTG trinucleotide repeat expan-
sion in the 3´ untranslated region of the Dystrophia Myoton-
ica Protein Kinase (DMPK) gene, which is assigned to 
chromosome band 19q13.2-q13.3 [5-9]. DM1 was the first 
dominantly inherited disease found to be caused by non-
coding repeat expansions; the mutation is transcribed into 
RNA but not translated into protein. Soon after, a second 
mutation in chromosome 3 was identified in patients with 
very similar symptoms that were classified as either Proxi-
mal Myotonic Myopathy (PROMM) or Myotonic Dystrophy 
type 2 (DM2) [10, 11]. DM2 was found associated with 
CCTG tetranucleotide repeat expansions in the first intron of  
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the Zinc Finger Protein 9 (ZNF9) gene ([10, 12] reviewed in 
[13]). Thus, DM1 and DM2 originate from long non-coding 
repeat expansions, which cause a similar chronic, slowly 
progressing, multisystemic disease with a dominant inheri-
tance pattern. If the proteins encoded by DMPK and ZNF9 
were normal, what was the molecular basis of the dominant 
phenotype?  
  In the last few years, a growing body of research, has 
resulted in a better understanding of the DM1 pathogenesis. 
Several excellent recent reviews appropriately update the 
reader to the current state of this knowledge [14]. In this pre-
sent review, we will specifically focus on the levels of gene 
expression regulation that mutant DMPK affects, namely 
gene transcription, alternative splicing, gene silencing and 
RNA translation, with particular emphasis on recent data.  
GENE TRANSCRIPTION CHANGES IN DM1:   
CIS-EFFECTS  
  Most dominant disorders are caused by the altered func-
tion of a mutant protein product so it was very difficult to 
explain how a mutation in a non-coding region could cause 
the multisystemic features of DM1. Since the discovery of 
the genetic mutation responsible for DM1, much effort has 
been devoted to precisely define whether DMPK transcripts 
and/or protein levels change in the presence of CTG expan-
sions. Initial reports using antisera and semiquantitative re-
verse transcriptase-polymerase chain reaction reported de-510    Current Genomics, 2008, Vol. 9, No. 8  Llamusí and Artero 
creased levels of both DMPK mRNA and protein in adult 
forms of DM1, suggesting that large CTG repeat expansions 
altered  DMPK mRNA synthesis and processing [15-18]. 
These observations and the detection of mutant DMPK tran-
scripts retained in the nucleus of DM fibroblasts and muscle 
biopsies supported the hypothesis of loss of DMPK function 
(DMPK haploinsufficiency) as the mechanism of pathogene-
sis of DM1 [19, 20]. However, subsequent improvements of 
protocols used for detection and quantification of total cyto-
plasmic mRNA levels reported that there was no significant 
change in DMPK transcription [21], and discovered that the 
anti-DMPK antisera used in previous reports crossreacted 
with other proteins [22]. Posterior studies confirmed that 
DMPK transcription was altered in patients and that there 
was no correlation between CTG repeat length and DMPK 
protein reduction [23-25]. 
  The functional implications of a reduction in DMPK 
expression were genetically tested with the generation of 
knockout mice.  DMPK
-/- mice develop a mild late-onset, 
progressive skeletal myopathy which suggested that DMPK 
might be necessary for the maintenance of skeletal muscle 
structure [26]. Subsequent studies showed that DMPK-
deficient mice also exhibited some cardiac conduction ab-
normalities [27] and metabolic impairment such as abnormal 
glucose tolerance, reduced glucose uptake and impaired in-
sulin-dependent GLUT4 trafficking in muscle [28]. As simi-
larly proposed for mutant DMPK, recent studies also suggest 
that haploinsufficiency of ZNF9 may contribute to the DM2 
disorder. ZNF9 knockout mice show phenotypes that resem-
ble DM, including muscle histopathology, myotonia and 
heart conduction abnormalities [29]. However, the fact that 
DMPK
-/- mice showed only a mild phenotype for just some 
of the DM symptoms and that no DMPK point mutations 
have been associated with a DM1 phenotype strongly sug-
gested that the multisystemic features of DM1 were not sim-
ply caused by DMPK haploinsufficiency.  
  The possibility that CTG and CCTG repeat expansions 
were altering the local structure of the chromatin (a cis-
effect; Fig. 1), thus interfering with the expression of DMPK 
and neighbouring genes, has also been considered. Immedi-
ately adjacent to DMPK are SIX5, which encodes a ho-
meodomain transcription factor, and myotonic dystrophy 
gene with WD repeats ( DMDW) that is prominently ex-
pressed in testis and brain [30-32]. The hypothesis is chiefly 
supported by the fact that DMDW expression levels are re-
ported decreased in repeat expansion bearing patients [31, 
33]. Moreover, mutant analysis in Drosophila has shown that 
D-Six4, the closest Six5 homolog in flies, is required for the 
normal development of muscle and the mesodermal compo-
nents of the gonad. This suggested that human Six5 could 
participate in muscle wasting and testicular atrophy pheno-
types in DM1 [34]. However, Six5 knockout mice only de-
velop cataracts that lack the distinctive iridescent opacities 
characteristic of cataracts from DM1 patients [35].  
GENE TRANSCRIPTION CHANGES IN DM1: 
TRANS-EFFECTS  
  Electron microscope examination has revealed that CUG 
repeat RNA forms double-stranded RNA (dsRNA) segments 
[36] that, additionally, are able to bind the dsRNA activated 
protein kinase PKR [37] and Muscleblind protein family 
members [38]. More recent crystallographic data have con-
firmed that CUG repeat RNA forms antiparallel double-
stranded helices similar in structure to A-form RNA except 
for the unique U-U-mismatches [39]. This peculiar structure 
supported an RNA dominant mutation model in which long 
dsRNAs gain the capacity to sequester certain RNA-binding 
proteins that are correspondingly depleted from their normal 
subcellular localizations.  
  A number of regulatory transcription factors (TFs) have 
been found to change their nuclear compartment distribution 
from active chromatin to CUG repeat-containing ribonuclear 
particles in a DM1 cell model, a process known as RNA 
leaching [40]. Measured fractions of Specificity protein 1 
(Sp1), Signal Transducer and Activator of Transcription 
(STAT1 and STAT3) and Retinoic Acid Receptor gamma 
(RAR) in the chromatin, were dramatically reduced after 
three weeks of mutant DMPK RNA expression. Diverse 
genes are consequently reduced in expression, including the 
muscle-specific  chlorine channel 1 (CLCN1), which has 
been involved in myotonia [40]. Another example of TF 
found to be altered by repeat expansions is MyoD. Levels of 
MyoD, a TF necessary for muscle differentiation and regen-
eration, are significantly reduced in myoblasts expressing the 
mutant 3'-UTR DMPK RNA [41]. Changes in TF activity 
should alter transcription of target genes (a trans-effect; Fig. 
1). Consistently, gene transcription changes in DM has been 
further verified by comparing the expression profile of mus-
cle biopsies from DM1 and DM2 patients to controls in a 
macroarray analysis of 96 neuroscience-related genes [42]. 
Six genes critical for calcium and potassium metabolism and 
mitochondrial functions were misregulated both in DM1 and 
DM2 also strengthening the current view that both diseases 
share a common pathogenetic pathway [42].  
  DM1 has been also associated with overexpression of the 
cardiac-specific transcription factor NK2 transcription factor 
related, locus 5 (Drosophila) (Nkx2-5), also known in Dro-
sophila as tinman. Levels of NKX2-5 increased in cardiac 
tissue in a reversible transgenic mouse model for RNA toxic-
ity [43]. Moreover, overexpression of DMPK 3' UTR mRNA 
in mouse skeletal muscle also induced transcriptional activa-
tion of Nkx2-5 and its targets. In human muscles these 
changes were specific to DM1 and were not present in other 
muscular dystrophies possibly contributing to the cardiac 
conduction degeneration found in DM [43].  
  Despite still limited experimental support, modification 
of TFs expression by leaching from chromatin or other 
mechanisms provides a powerful explanation for broad gene 
expression changes, especially if their effects add on alterna-
tive splicing changes already known to occur in DM1 (see 
below). A requirement for general transcription factors in 
different tissues that express DMPK would account for the 
multisystemic and multisymptomatic nature of DM1. 
Moreover, a common trans-acting mechanism with trapping 
and depletion of similar TFs might contribute to the clinical 
analogies between DM1 and DM2.  
CUG REPEAT RNA SEQUESTERS ALTERNATIVE 
SPLICING FACTORS  
  The identification of RNA-binding proteins bound to 
CUG repeat expansions clearly suggested an RNA-gain-of Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica  Current Genomics, 2008, Vol. 9, No. 8    511 
function model for DM1 [38] and provided a molecular ex-
planation for the phenotypical similarities between DM1 and 
DM2 since the same, or similar RNA-binding proteins, could 
get sequestered by mutant CUG and CCUG repeat RNA. 
Several studies have established that one of the reasons for 
the toxicity of mutant DMPK RNA is that it interferes with 
the activity of human Muscleblind-like 1, 2 and 3 (MBNL1-
3) proteins. MBNL proteins were directly implicated in DM1 
pathogenesis when they were found to specifically bind 20 
CUG trinucleotide repeats or longer in vitro in HeLa cell 
extracts [38]. MBNL proteins are orthologous to the Droso-
phila Muscleblind proteins, which are required for terminal 
differentiation of muscle and photoreceptor cells [44, 45]. 
Co-localization studies in both cell and tissue samples from 
DM1 and DM2 patients showed that MBNL1-3 were re-
tained in the cell nucleus as ribonuclear foci that included 
mutant transcripts [46-52]. Drosophila Muscleblind similarly 
co-localized with CUG ribonuclear foci in muscle cells in 
DM1 fly models [53-55]. Human MBNL proteins seem to 
have acquired specialized functions although all three were 
capable of regulating the use of alternative exons in cardiac 
troponin T (cTNT) and insulin receptor (IR) transcripts [56]. 
While MBNL1 is involved in promoting muscle differentia-
tion, MBNL3 represses it and MBNL2 participates in the 
subcellular localization of alpha3-integrin transcripts [38, 
57, 58]. Extensive alternative splicing in the MBNL1, 2 and 
3 genes generates at least nine, three and six protein iso-

















Fig. (1). CTG trinucleotide expansions interfere with gene expression regulation at several levels. The genomic organization around 
CTG expansions is represented at the top of the figure, with boxes denoting genes and a line representing the intergenic DNA. CTG-induced 
local changes in chromatin organization may explain reduced transcription in DMPK, Six5 and DMDW genes (“Cis-effect”). Upon transcrip-
tion, non-coding CTG expansions fold themselves into dsRNA hairpins in the cell nucleus that aberrantly bind different types of nuclear 
factors (box, rectangle, small oval and circle). Nuclear retention of mutant DMPK transcripts and activity of Dicer ribonuclease may also 
contribute to the reduction in DMPK expression. Sequestration of transcription factors (“RNA leaching of TFs”), and in particular Sp1, has 
been shown to reduce transcription originating from the CLCN1 promoter. Aberrant binding of MBNL1 to the ds(CUG) hairpins sequesters 
the protein. Steady-state levels of nuclear CUG-BP1 increase by protein kinase C mediated phosphorylation. Both effects result in unbal-
anced cytoplasmic levels of these antagonic alternative splicing (AS) regulators leading to changes in the transcript isoforms originating from 
several pre-mRNAs (examples listed in the boxes under the “Skeletal muscle”, “Heart” and “Brain” labels). A combination of nuclear stabi-
lization and changes in key phosphorylation events likely explain the inefficient activation of p21, Mef2A and C/EBP mRNA translation by 
cytoplasmic CUG-BP1. ds(CUG) hairpins are a substrate for the Dicer ribonuclease, which reduces levels of mutant DMPK simultaneously 
generating CUG siRNA with the ability to silence transcripts containing complementary CAG repeats such as those of the Huntington Dis-
ease and Spinocerebellar ataxia genes. The figure includes both human and mouse genes, the expression of which is known to be altered in 
DM1 or animal models of the disease. 512    Current Genomics, 2008, Vol. 9, No. 8  Llamusí and Artero 
Consistent with the involvement of MBNL proteins in the 
RNA gain of function mechanism, Mbnl1 knockdown mice 
[60] showed DM1-like phenotypes including iridescent cata-
racts, myotonia and missplicing of muscle transcripts that 
had been reported altered in DM1 patients such as IR and 
CLC-1 pre-mRNA [61, 62]. muscleblind mutant embryos 
similarly showed altered expression of muscle transcript 
isoforms from the Drosophila ZASP homologue and alpha-
actinin genes [63]. More recently, the generation of a Mbnl2-
deficient mouse also displaying myotonia, skeletal muscle 
pathology consistent with human DM, and reduced expres-
sion of CLC-1 mRNA in skeletal muscle, suggests that de-
pletion of MBNL2 might also contribute to the human DM 
pathogenesis [64]. Conversely, overexpression of MBNL1 in 
vivo using a recombinant adeno-associated viral vector res-
cued disease-associated muscle myotonia and adult-splicing 
patterns of muscle pre-mRNAs characteristically misspliced 
in transgenic mice expressing 250 CTG repeats in the 3´UTR 
of a human skeletal alpha-actin transcript. These results 
support the hypothesis that loss of MBNL1 activity is a pri-
mary pathogenic event in the development of the disease 
[65].  
  CUG repeat expansions interfere with the activity of al-
ternative splicing factors other than Muscleblind. CUG-BP1 
and ETR-3 like factor (CELF) member CUG-BP1 does not 
bind ds(CUG) hairpins nor co-localizes with ribonuclear foci 
but its activity is increased in DM1 myoblasts, skeletal mus-
cle, and heart tissues [36, 66, 67] (see [68] for a review about 
CELF RNA binding proteins). Although the molecular 
mechanism leading to CUG-BP1 activation is not completely 
understood, inappropriate activation of the protein kinase C 
(PKC) pathway contributes to the pathogenic effect of non-
coding CUG repeat RNA through hyperphosphorylation of 
nuclear CUG-BP1, which is stabilized in this cellular com-
partment [69]. Transgenic mice that overexpress CUG-BP1 
in muscle and heart reproduce missplicing alterations typical 
of DM1, which has confirmed the involvement of this pro-
tein in the pathogenesis of the disease as well as the antago-
nism between MBNL1 and CUG-BP1 in alternative splicing 
regulation ([70] and below). 
  Results from several groups support that increased activ-
ity of CUG-BP1 in DM1 is pathogenic as CUG-BP1 regu-
lates alternative splicing of pre-mRNA transcripts antagoniz-
ing Muscleblind activity [67, 71-73]. Another splicing regu-
lator altered by CUG repeat expansions is heterogeneous 
nuclear ribonucleoprotein H (hnRNP H). The protein was 
identified in UV-crosslinking assays as a factor capable of 
binding and modulating nuclear retention of mutant DMPK 
mRNA. The specific binding of hnRNP H requires not only 
a CUG expansion but also a splicing branch point distal to 
the repeats [73]. It has been proposed that in normal 
myoblast hnRNP H and CUG-BP1 form an RNA-dependent 
complex required to maximally inhibit IR exon 11 inclusion, 
which is counteracted by the exon 11 splice enhancing activ-
ity of Muscleblind proteins [74]. Because Muscleblind pro-
teins are required facilitators of IR exon 11, exclusion of 
exon 11 in IR transcripts is a typical splicing misregulation 
event in DM1 [61].  
  Given the involvement of alternative splicing regulators 
Muscleblind, CUG-BP1 and hnRNP H, it is not surprising 
that a defining molecular alteration in DM1 is missplicing of 
a defined set of muscle, brain and heart transcripts (for a 
compilation of splice alterations in DM1 see [75]). Changes 
in tissue-specific splice patterns have been shown to contrib-
ute to particular symptoms in DM1 patients. Myotonia has 
been attributed to reduced expression of Clcn1 due to the 
combined effects of a decrease in transcription from the 
Clcn1 gene and inclusion of alternative exon 7a, which in-
cludes a TGA stop codon that triggers non-sense mediated 
decay [76]. Indeed, patch clamp analysis has confirmed that 
myotonia is associated with a marked reduction in chloride 
channel activity [77] thus suggesting that reduction in tran-
scription and generation of protein variants with no intrinsic 
channel activity originate myotonia [50, 77, 78]. The number 
of genes and alternative exons altered in DM1 is still un-
known, but the data available support a view in which the 
process of constitutive RNA processing is not affected in 
DM1 cells [56, 79, 80]. During embryonic development and 
postnatal periods in mammals, a series of changes are re-
quired at the transcriptional and post-transcriptional levels 
that account for the remodeling necessary for the adult body 
development [81]. Some of these changes are based on the 
alternative splicing of many transcripts in these tissues, 
which are regulated by RNA binding proteins including 
members of the Muscleblind and CELF families. Activation 
of MBNL1 during muscle differentiation stages brings about 
the exclusion of fetal exons from multiple RNA transcripts 
leading to their adult encoding isoforms [82, 83]. Indeed, the 
DM pathology seems to selectively affect a defined set of 
pre-mRNAs that undergo such developmentally regulated 
switch in their alternative splicing pattern. Failure to switch 
on an adult-type alternative splicing pattern, due to lack of 
Muscleblind function, results in the maintenance of a fetal-
like splicing pattern in adult tissue [82, 83]. A trans-effect on 
the alternative splicing of many RNAs that leads to the 
expression of splice products developmentally inappropriate 
for a particular tissue has been recently termed spliceopathy 
[75] being DM1 the first example of spliceopathy in humans 
(Fig. 1).  
  Although the notion of MBNL1 sequestration by CUG 
repeats is certainly the best established, a number of results 
suggest that the toxic effect caused by CUG-repeat expan-
sion RNAs might involve more than just Muscleblind se-
questration. First, disruption of MBNL1-regulated splicing 
and formation of RNA foci are separable events in cell cul-
ture conditions. Both CUG and CAG repeat expansions form 
ribonuclear foci that colocalize with MBNL1 in COSM6 
cells, but only CUG repeats disrupt MBNL1-regulated splic-
ing [84]. Second, MBNL1 bound 70 CAG repeats in a yeast 
three-hybrid assay [85] whereas 162 CUG repeats readily 
sequestered Muscleblind but failed to induce any discernible 
phenotype in a Drosophila DM1 model [53]. Finally, it has 
been recently shown that non-coding CAG repeat RNA of 
pathogenic length induced progressive neural dysfunction in 
Drosophila but, as similarly reported by Ho et al 2005, 270 
CAG repeats did not change the profile of alternative splic-
ing of a reporter construct [84, 86].  
  Among genetic diseases the therapeutic opportunities in 
DM1 are particularly favourable because elimination of toxic 
RNA reversed cardinal features of DM1 in a transgenic mice 
model. Overexpression of a normal DMPK 3´UTR (five 
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reported to cause myotonia, cardiac conduction abnormali-
ties, histopathology and RNA splicing defects in the absence 
of detectable nuclear inclusions. Five CUG repeats were 
apparently sufficient to originate DM1-like phenotypes 
without formation of RNA or Mbnl nuclear foci. In these 
transgenic mice CUG-BP1 levels were found increased in 
skeletal muscle while no change in Mbnl1 was detected. Al-
though surprising, the authors explained the DM1 phenotype 
by the unbalance between CUG-BP1 (upregulated) and 
Mbnl1 (unchanged) antagonistic activities as alternative 
splicing regulators resulting in missplicing of characteristic 
transcripts such as ClC-1 and cTNT [72]. The mapping of 
MBNL1-binding sites upstream of their normal splicing tar-
gets, however, offers an alternative view. RNA recognition 
by MBNL proteins involves a common mechanism for both 
normal targets and pathogenic repeats, which implies recog-
nition of GC-rich hairpins containing pyrimidine mismatches 
[87]. Results from this work suggest that below a certain 
length threshold (<20 repeats), the A-helix structure formed 
by dsCUG [39] is unstable and that ssCUG are not appropri-
ate binding targets for MBNL1. It seems that MBNL1 rec-
ognizes relatively short GC-rich hairpins (18 nucleotides) 
only if the overall RNA secondary structure is stabilized by 
additional sequence interactions [87]. Thus, overexpression 
of CUG repeats within the normal range, such as for exam-
ple in the inducible model reported by the Mahadevan´s 
group [72], might readily divert MBNL1 from their normal 
targets in the absence of long CUG expansions.  
GENE SILENCING: dsCUG EXPANSIONS ARE 
DICER TARGETS  
  The double stranded nature of CUG repeat expansions in 
vivo prompted speculations as for the possibility that might 
act as a Dicer ribonuclease target thus generating small inter-
fering RNAs (siRNAs) that would silence transcripts con-
taining complementary, or near complementary sequences 
(Fig. 1) [88]. Suggestively, MBNL1 protein itself includes a 
run of seven alanines encoded by a sequence with the poten-
tial to act as target of CUG siRNAs. In vitro studies in HeLa 
cells have already shown that the mechanism that permits the 
specific silencing of target RNAs by siRNA and miRNA is 
active in the cell nucleus [89]. Indeed, Krol and co-workers 
[90] have shown that transcripts containing long hairpin 
structures composed of CNG repeats are a class of Dicer 
ribonuclease targets. Dicer activity elicits two opposing ef-
fects in DM fibroblast cells [90]. On the one hand, the activ-
ity of the ribonuclease downregulates the mutant DMPK 
transcript, which removes a toxic RNA from the cell and 
may contribute to the reduction of DMPK expression levels. 
On the other hand, the Dicer-induced short CUG repeats 
generated act as siRNAs and use the RNA interference 
pathway to silence expression of transcripts containing long 
complementary repeats, which may add up to potentially 
pathogenic gene expression unbalances.  
EFFECTS ON mRNA TRANSLATION  
  CUG-BP1 is a multifunctional RNA-binding protein that 
regulates RNA processing at several stages including activat-
ing cap-dependent and cap-independent translation, RNA 
stability and splicing [83, 91]. Although it was already 
known that cytoplasmic CUG-BP1 could promote translation 
of p21 [92], C/EBP [93] and Mef2A [70] in differentiating 
cells by interacting with translation initiation factor eIF2, the 
mechanism by which translation was inefficient in DM1 
muscle cells was not fully understood, in particular after con-
firming that the levels of CUG-BP1 mRNA did not show any 
significant change in DM1 muscle cells when compared to 
normal myoblasts [94]. In a recent paper Salisbury and co-
workers [91] showed that two key phosphorylation events in 
CUG-BP1 were mis-regulated during DM1 myogenesis. 
Serine/threonine-specific protein kinase family member Akt 
phosphorylated CUG-BP1 at Ser28 and increased interaction 
of CUG-BP1 with cyclin D1 mRNA, which is a strong pro-
moter of cell proliferation. CUG-BP1 was also phosphory-
lated at Ser302 by cyclinD3/cdk4 complexes. Phosphoryla-
tion of CUG-BP1 by cyclinD3/cdk4 increased interactions of 
CUG-BP1 with C/EBPbeta and p21 mRNAs. Cyclin D3-
cdk4-mediated phosphorylation of CUG-BP1 increased for-
mation of the translational CUG-BP1-eIF2 complexes during 
normal muscle differentiation. Because examination of DM1 
cells revealed that both cyclin D3 and cdk4 levels did not 
increase in DM1 differentiating cells, reduction in formation 
of the translational complex CUG-BP1-eIF2 provides a rea-
sonable explanation for the reduction in p21 and Mef2A 
translation in DM1 myoblasts. Confirmation that cyclinD3/ 
cdk4 was implicated in CUG-BP1 translational control came 
from experiments in which ectopic expression of cyclin D3 
corrected the differentiation of DM1 myocytes [91]. Failure 
to express cell cycle arrest control p21 protein, as well as 
others with similar function, correlates well with defective 
withdraw from cell cycle of cultured DM muscle cells, a 
necessary step for muscle differentiation [66]. Furthermore, 
whereas differentiated normal myoblasts accumulated CUG-
BP1 in the cytoplasm, skeletal muscle cells from DM1 pa-
tients failed to induce cytoplasmic levels of a CUG RNA 
binding protein, also contributing to the inhibition of transla-
tion of key muscle and cell cycle transcripts [66].  
PERSPECTIVES  
  The toxic RNA hypothesis is now a well established 
model to explain the pathogenic effect of mutant DMPK 
transcripts and is being extended to other trinucleotide dis-
eases such as Fragile X Tremor Ataxia Syndrome, Spi-
nocerebelar Ataxia 3 (SCA3), or Huntington´s Disease-Like 
2 (HDL-2) among other disorders [86, 95, 96]. Despite the 
fact that it builds on results obtained over more than a dec-
ade of work, a number of key issues still deserve immediate 
attention. First, low through-put technologies applied so far 
provide a low resolution picture of the complex pattern of 
gene transcription changes taking place in the disease state. 
Use of microarray and/or ultrasequencing technologies 
should provide an accurate genome-wide description of gene 
changes both at the transcription and pre-mRNA maturation 
levels, with the possibility of identifying new, unexpected, 
additional levels of complexity in the disease. Second, recent 
results indicate that key signal transduction components such 
as protein kinase C and Akt become altered in DM1 cells 
[69, 91]. Whether this is a primary or secondary effect of 
CUG repeat RNA remains to be determined as well as the 
relevance of signal transduction changes to the regulation of 
activity of alternative splicing factors themselves. Finally, 
the generation of improved animal models for Myotonic 514    Current Genomics, 2008, Vol. 9, No. 8  Llamusí and Artero 
Dystrophy should allow for the development and evaluation 
of effective therapies. In the last few years DM models in 
Drosophila, mice and C.elegans have been generated and 
tested for several potential treatments ranging from activa-
tion of the RNA interference pathway to the administration 
of chemical compounds [55, 72, 97-99]. Development of and 
effective anti-DM1 treatment will require to further explore 
these and newer experimental therapies in animal models, as 
well as keep untangling the still unexplored complexity of 
this multifaceted disease. 
ACKNOWLEDGEMENTS  
  We thank Patrick Morcillo and members of our labora-
tory for insightful discussions during the writing of this pa-
per. The financial support to B.L. by the Genoma España 
Foundation is also acknowledged.  
REFERENCES 
[1]  Machuca-Tzili, L., Brook, D., Hilton-Jones, D. Clinical and mo-
lecular aspects of the myotonic dystrophies: a review. Muscle 
Nerve 2005, 32: 1-18. 
[2]  Gagnon, C., Noreau, L., Moxley, R.T., Laberge, L., Jean, S., 
Richer, L., Perron, M., Veillette, S., Mathieu, J. Towards an inte-
grative approach to the management of myotonic dystrophy type 1. 
J. Neurol. Neurosurg. Psychiatr. 2007, 78: 800-6. 
[3]  Mathieu, J., De Braekeleer, M., Prevost, C. Genealogical recon-
struction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean 
area (Quebec, Canada). Neurology 1990, 40: 839-42. 
[4]  Myotonic dystrophy, 3
rd ed, by P. Harper, pp. 436, ill., London, 
W.B. Saunders, 2001.  
[5]  Shutler, G., Korneluk, R.G., Tsilfidis, C., Mahadevan, M., Bailly, 
J., Smeets, H., Jansen, G., Wieringa, B., Lohman, F., Aslanidis, C. 
Physical mapping and cloning of the proximal segment of the myo-
tonic dystrophy gene region. Genomics 1992, 13: 518-25. 
[6]  Fu, Y.H., Pizzuti, A., Fenwick, R.G., Jr., King, J., Rajnarayan, S., 
Dunne, P.W., Dubel, J., Nasser, G.A., Ashizawa, T., de Jong, P. An 
unstable triplet repeat in a gene related to myotonic muscular dys-
trophy. Science 1992, 255: 1256-8. 
[7]  Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, 
C., Jansen, G., Neville, C., Narang, M., Barcelo, J., O'Hoy, K. 
Myotonic dystrophy mutation: an unstable CTG repeat in the 3' un-
translated region of the gene. Science 1992, 255: 1253-5. 
[8]  Brook, J.D., McCurrach, M.E., Harley, H.G., Buckler, A.J., 
Church, D., Aburatani, H., Hunter, K., Stanton, V.P., Thirion, J.P., 
Hudson, T. Molecular basis of myotonic dystrophy: expansion of a 
trinucleotide (CTG) repeat at the 3' end of a transcript encoding a 
protein kinase family member. Cell 1992, 69: 385. 
[9]  Aslanidis, C., Jansen, G., Amemiya, C., Shutler, G., Mahadevan, 
M., Tsilfidis, C., Chen, C., Alleman, J., Wormskamp, N.G., Vooijs, 
M. Cloning of the essential myotonic dystrophy region and map-
ping of the putative defect. Nature 1992, 355: 548-51. 
[10]  Ranum, L.P., Rasmussen, P.F., Benzow, K.A., Koob, M.D., Day, 
J.W. Genetic mapping of a second myotonic dystrophy locus. Nat. 
Genet. 1998, 19: 196-8. 
[11]  Liquori, C.L., Ricker, K., Moseley, M.L., Jacobsen, J.F., Kress, W., 
Naylor, S.L., Day, J.W., Ranum, L.P. Myotonic dystrophy type 2 
caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 
293: 864-7. 
[12]  Ranum, L.P., Day, J.W. Dominantly inherited, non-coding micro-
satellite expansion disorders. Curr. Opin. Genet. Dev.  2002,  12: 
266-71. 
[13]  Day, J.W., Ranum, L.P. RNA pathogenesis of the myotonic dystro-
phies. Neuromuscul. Disord. 2005, 15: 5-16. 
[14]  Kaliman, P., Llagostera, E. Myotonic dystrophy protein kinase 
(DMPK) and its role in the pathogenesis of myotonic dystrophy 1. 
Cell Signal 2008, May 18 [Epub ahead of print]. 
[15]  Fu, Y.H., Friedman, D.L., Richards, S., Pearlman, J.A., Gibbs, 
R.A., Pizzuti, A., Ashizawa, T., Perryman, M.B., Scarlato, G., 
Fenwick, R.G., Jr. Decreased expression of myotonin-protein 
kinase messenger RNA and protein in adult form of myotonic dys-
trophy. Science 1993, 260: 235-8. 
[16]  Hofmann-Radvanyi, H., Lavedan, C., Rabes, J.P., Savoy, D., 
Duros, C., Johnson, K., Junien, C. Myotonic dystrophy: absence of 
CTG enlarged transcript in congenital forms, and low expression of 
the normal allele. Hum. Mol. Genet. 1993, 2: 1263-6. 
[17]  Novelli, G., Gennarelli, M., Zelano, G., Pizzuti, A., Fattorini, C., 
Caskey, C.T., Dallapiccola, B. Failure in detecting mRNA tran-
scripts from the mutated allele in myotonic dystrophy muscle. Bio-
chem. Mol. Biol. Int. 1993, 29: 291-7. 
[18]  Carango, P., Noble, J.E., Marks, H.G., Funanage, V.L. Absence of 
myotonic dystrophy protein kinase (DMPK) mRNA as a result of a 
triplet repeat expansion in myotonic dystrophy. Genomics  1993, 
18: 340-8. 
[19]  Taneja, K.L., McCurrach, M., Schalling, M., Housman, D., Singer, 
R.H. Foci of trinucleotide repeat transcripts in nuclei of myotonic 
dystrophy cells and tissues. J. Cell Biol. 1995, 128: 995-1002. 
[20]  Davis, B.M., McCurrach, M.E., Taneja, K.L., Singer, R.H., 
Housman, D.E. Expansion of a CUG trinucleotide repeat in the 3' 
untranslated region of myotonic dystrophy protein kinase tran-
scripts results in nuclear retention of transcripts. Proc. Natl. Acad. 
Sci. USA 1997, 94: 7388-93. 
[21]  Eriksson, M., Ansved, T., Edstrom, L., Anvret, M., Carey, N. Si-
multaneous analysis of expression of the three myotonic dystrophy 
locus genes in adult skeletal muscle samples: the CTG expansion 
correlates inversely with DMPK and 59 expression levels, but not 
DMAHP levels. Hum. Mol. Genet. 1999, 8: 1053-60. 
[22]  Narang, M.A., Waring, J.D., Sabourin, L.A., Korneluk, R.G. Myo-
tonic dystrophy (DM) protein kinase levels in congenital and adult 
DM patients. Eur. J. Hum. Genet. 2000, 8: 507-12. 
[23]  Salvatori, S., Fanin, M., Trevisan, C.P., Furlan, S., Reddy, S., 
Nagy, J.I., Angelini, C. Decreased expression of DMPK: correla-
tion with CTG repeat expansion and fibre type composition in 
myotonic dystrophy type 1. Neurol. Sci. 2005, 26: 235-42. 
[24]  Hamshere, M.G., Newman, E.E., Alwazzan, M., Athwal, B.S., 
Brook, J.D. Transcriptional abnormality in myotonic dystrophy af-
fects DMPK but not neighboring genes. Proc. Natl. Acad. Sci. USA 
1997, 94: 7394-9. 
[25]  Tiscornia, G., Mahadevan, M.S. Myotonic dystrophy: the role of 
the CUG triplet repeats in splicing of a novel DMPK exon and al-
tered cytoplasmic DMPK mRNA isoform ratios. Mol. Cell 2000, 5: 
959-67. 
[26]  Reddy, S., Smith, D.B., Rich, M.M., Leferovich, J.M., Reilly, P., 
Davis, B.M., Tran, K., Rayburn, H., Bronson, R., Cros, D. Mice 
lacking the myotonic dystrophy protein kinase develop a late onset 
progressive myopathy. Nat. Genet. 1996, 13: 325-35. 
[27]  Berul, C.I., Maguire, C.T., Gehrmann, J., Reddy, S. Progressive 
atrioventricular conduction block in a mouse myotonic dystrophy 
model. J. Interv. Card. Electrophysiol. 2000, 4: 351-8. 
[28]  Llagostera, E., Catalucci, D., Marti, L., Liesa, M., Camps, M., 
Ciaraldi, T.P., Kondo, R., Reddy, S., Dillmann, W.H., Palacin, M. 
Role of myotonic dystrophy protein kinase (DMPK) in glucose 
homeostasis and muscle insulin action. PLoS ONE. 2007, 2: e1134. 
[29]  Chen, W., Wang, Y., Abe, Y., Cheney, L., Udd, B., Li, Y.P. Hap-
loinsuffciency for Znf9 in Znf9+/- mice is associated with multior-
gan abnormalities resembling myotonic dystrophy. J. Mol. Biol. 
2007, 368: 8-17. 
[30]  Winchester, C.L., Ferrier, R.K., Sermoni, A., Clark, B.J., Johnson, 
K.J. Characterization of the expression of DMPK and SIX5 in the 
human eye and implications for pathogenesis in myotonic dystro-
phy. Hum. Mol. Genet. 1999, 8: 481-92. 
[31]  Alwazzan, M., Newman, E., Hamshere, M.G., Brook, J.D. Myo-
tonic dystrophy is associated with a reduced level of RNA from the 
DMWD allele adjacent to the expanded repeat. Hum. Mol. Genet. 
1999, 8: 1491-7. 
[32]  Junghans, R.P., Ebralidze, A., Tiwari, B. Does (CUG)n repeat in 
DMPK mRNA 'paint' chromosome 19 to suppress distant genes to 
create the diverse phenotype of myotonic dystrophy? A new hy-
pothesis of long-range cis autosomal inactivation. Neurogenetics 
2001, 3: 59-67. 
[33]  Gennarelli, M., Pavoni, M., Amicucci, P., Angelini, C., Mene-
gazzo, E., Zelano, G., Novelli, G., Dallapiccola, B. Reduction of 
the DM-associated homeo domain protein (DMAHP) mRNA in 
different brain areas of myotonic dystrophy patients. Neuromuscul. 
Disord. 1999, 9: 215-9. Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica  Current Genomics, 2008, Vol. 9, No. 8    515 
[34]  Kirby, R.J., Hamilton, G.M., Finnegan, D.J., Johnson, K.J., Jarman, 
A.P. Drosophila homolog of the myotonic dystrophy-associated 
gene, SIX5, is required for muscle and gonad development. Curr. 
Biol. 2001, 11: 1044-9. 
[35]  Klesert, T.R., Cho, D.H., Clark, J.I., Maylie, J., Adelman, J., 
Snider, L., Yuen, E.C., Soriano, P., Tapscott, S.J. Mice deficient in 
Six5 develop cataracts: implications for myotonic dystrophy. Nat. 
Genet. 2000, 25: 105-9. 
[36]  Michalowski, S., Miller, J.W., Urbinati, C.R., Paliouras, M., Swan-
son, M.S., Griffith, J. Visualization of double-stranded RNAs from 
the myotonic dystrophy protein kinase gene and interactions with 
CUG-binding protein. Nucleic. Acids. Res. 1999, 27: 3534-42. 
[37]  Tian, B., White, R.J., Xia, T., Welle, S., Turner, D.H., Mathews, 
M.B., Thornton, C.A. Expanded CUG repeat RNAs form hairpins 
that activate the double-stranded RNA-dependent protein kinase 
PKR. RNA. 2000, 6: 79-87. 
[38]  Miller, J.W., Urbinati, C.R., Teng-Umnuay, P., Stenberg, M.G., 
Byrne, B.J., Thornton, C.A., Swanson, M.S. Recruitment of human 
muscleblind proteins to (CUG)(n) expansions associated with myo-
tonic dystrophy. EMBO J. 2000, 19: 4439-48. 
[39]  Mooers, B.H., Logue, J.S., Berglund, J.A. The structural basis of 
myotonic dystrophy from the crystal structure of CUG repeats. 
Proc. Natl. Acad. Sci. USA 2005, 102: 16626-31. 
[40]  Ebralidze, A., Wang, Y., Petkova, V., Ebralidse, K., Junghans, R.P. 
RNA leaching of transcription factors disrupts transcription in 
myotonic dystrophy. Science 2004, 303: 383-7. 
[41]  Amack, J.D., Reagan, S.R., Mahadevan, M.S. Mutant DMPK 3'-
UTR transcripts disrupt C2C12 myogenic differentiation by com-
promising MyoD. J. Cell Biol. 2002, 159: 419-29. 
[42]  Botta, A., Vallo, L., Rinaldi, F., Bonifazi, E., Amati, F., Bian-
colella, M., Gambardella, S., Mancinelli, E., Angelini, C., Meola, 
G. Gene expression analysis in myotonic dystrophy: indications for 
a common molecular pathogenic pathway in DM1 and DM2. Gene 
Expr. 2007, 13: 339-51. 
[43]  Yadava, R.S., Frenzel-McCardell, C.D., Yu, Q., Srinivasan, V., 
Tucker, A.L., Puymirat, J., Thornton, C.A., Prall, O.W., Harvey, 
R.P., Mahadevan, M.S. RNA toxicity in myotonic muscular dys-
trophy induces NKX2-5 expression. Nat. Genet. 2008, 40: 61-8. 
[44]  Begemann, G., Paricio, N., Artero, R., Kiss, I., Perez-Alonso, M., 
Mlodzik, M. muscleblind, a gene required for photoreceptor differ-
entiation in Drosophila, encodes novel nuclear Cys3His-type zinc-
finger-containing proteins. Development 1997, 124: 4321-31. 
[45]  Artero, R., Prokop, A., Paricio, N., Begemann, G., Pueyo, I., Mlod-
zik, M., Perez-Alonso, M., Baylies, M.K. The muscleblind gene 
participates in the organization of Z-bands and epidermal attach-
ments of Drosophila muscles and is regulated by Dmef2. Dev. Biol. 
1998, 195: 131-43. 
[46]  Fardaei, M., Larkin, K., Brook, J.D., Hamshere, M.G. In vivo co-
localisation of MBNL protein with DMPK expanded-repeat tran-
scripts. Nucleic Acids Res. 2001, 29: 2766-71. 
[47]  Fardaei, M., Rogers, M.T., Thorpe, H.M., Larkin, K., Hamshere, 
M.G., Harper, P.S., Brook, J.D. Three proteins, MBNL, MBLL and 
MBXL, co-localize in vivo with nuclear foci of expanded-repeat 
transcripts in DM1 and DM2 cells. Hum. Mol. Genet. 2002, 11: 
805-14. 
[48]  Mankodi, A., Urbinati, C.R., Yuan, Q.P., Moxley, R.T., Sansone, 
V., Krym, M., Henderson, D., Schalling, M., Swanson, M.S., 
Thornton, C.A. Muscleblind localizes to nuclear foci of aberrant 
RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 2001, 
10: 2165-70. 
[49]  Mankodi, A., Lin, X., Blaxall, B.C., Swanson, M.S., Thornton, 
C.A. Nuclear RNA foci in the heart in myotonic dystrophy. Circ. 
Res. 2005, 97: 1152-5. 
[50]  Jiang, H., Mankodi, A., Swanson, M.S., Moxley, R.T., Thornton, 
C.A. Myotonic dystrophy type 1 is associated with nuclear foci of 
mutant RNA, sequestration of muscleblind proteins and deregu-
lated alternative splicing in neurons. Hum. Mol. Genet. 2004, 13: 
3079-88. 
[51]  Cardani, R., Mancinelli, E., Rotondo, G., Sansone, V., Meola, G. 
Muscleblind-like protein 1 nuclear sequestration is a molecular pa-
thology marker of DM1 and DM2. Eur. J. Histochem. 2006, 50: 
177-82. 
[52]  Wheeler, T.M., Krym, M.C., Thornton, C.A. Ribonuclear foci at 
the neuromuscular junction in myotonic dystrophy type 1. Neuro-
muscul. Disord. 2007, 17: 242-7. 
[53]  Houseley, J.M., Wang, Z., Brock, G.J., Soloway, J., Artero, R., 
Perez-Alonso, M., O'Dell, K.M., Monckton, D.G. Myotonic dys-
trophy associated expanded CUG repeat muscleblind positive ribo-
nuclear foci are not toxic to Drosophila. Hum. Mol. Genet. 2005, 
14: 873-83. 
[54]  Haro, M.D., Al-Ramahi, I., Gouyon, B.D., Ukani, L., Rosa, A., 
Faustino, N.A., Ashizawa, T., Cooper, T.A., Botas, J. MBNL1 and 
CUGBP1 modify expanded CUG-induced toxicity in a Drosophila 
model of Myotonic Dystrophy Type 1. Hum. Mol. Genet.  2006, 
15: 2138-45. 
[55]  Garcia-Lopez, A., Monferrer, L., Garcia-Alcover, I., Vicente-
Crespo, M., Alvarez-Abril, M.C., Artero, R.D. Genetic and chemi-
cal modifiers of a CUG toxicity model in Drosophila. PLoS ONE. 
2008, 3: e1595. 
[56]  Ho, T.H., Charlet, B.N., Poulos, M.G., Singh, G., Swanson, M.S., 
Cooper, T.A. Muscleblind proteins regulate alternative splicing. 
EMBO J. 2004, 23: 3103-12. 
[57]  Squillace, R.M., Chenault, D.M., Wang, E.H. Inhibition of muscle 
differentiation by the novel muscleblind-related protein CHCR. 
Dev. Biol. 2002, 250: 218-30. 
[58]  Adereth, Y., Dammai, V., Kose, N., Li, R., Hsu, T. RNA-
dependent integrin 3 protein localisation regulated by the Mus-
cleblind-like protein MLP1. Nat. Cell Biol. 2005, 7: 1240-7. 
[59]  Pascual, M., Vicente, M., Monferrer, L., Artero, R. The Muscle-
blind family of proteins: an emerging class of regulators of devel-
opmentally programmed alternative splicing. Differentiation 2006, 
74: 65-80. 
[60]  Kanadia, R.N., Johnstone, K.A., Mankodi, A., Lungu, C., Thorn-
ton, C.A., Esson, D., Timmers, A.M., Hauswirth, W.W., Swanson, 
M.S. A muscleblind knockout model for myotonic dystrophy. Sci-
ence 2003, 302: 1978-80. 
[61]  Savkur, R.S., Philips, A.V., Cooper, T.A. Aberrant regulation of 
insulin receptor alternative splicing is associated with insulin resis-
tance in myotonic dystrophy. Nat. Genet. 2001, 29: 40-7. 
[62]  Charlet, B.N., Savkur, R.S., Singh, G., Philips, A.V., Grice, 
E.A.,Cooper, T.A. Loss of the muscle-specific chloride channel in 
type 1 myotonic dystrophy due to misregulated alternative splicing. 
Mol. Cell 2002, 10: 45-53. 
[63]  Machuca-Tzili, L., Thorpe, H., Robinson, T.E., Sewry, C., Brook, 
J.D. Flies deficient in Muscleblind protein model features of myo-
tonic dystrophy with altered splice forms of Z-band associated 
transcripts. Hum. Genet. 2006, 120: 487-499. 
[64]  Hao, M., Akrami, K., Wei, K., De Diego, C., Che, N., Ku, J.H., 
Tidball, J., Graves, M.C., Shieh, P.B., Chen, F. Muscleblind-like 2 
(Mbnl2) -deficient mice as a model for myotonic dystrophy. Dev. 
Dyn. 2008, 237: 403-10. 
[65]  Kanadia, R.N., Shin, J., Yuan, Y., Beattie, S.G., Wheeler, T.M., 
Thornton, C.A., Swanson, M.S. Reversal of RNA missplicing and 
myotonia after muscleblind overexpression in a mouse poly(CUG) 
model for myotonic dystrophy. Proc. Natl. Acad. Sci. USA 2006, 
103: 11748-53. 
[66]  Timchenko, N.A., Cai, Z.J., Welm, A.L., Reddy, S., Ashizawa, T., 
Timchenko, L.T. RNA CUG repeats sequester CUGBP1 and alter 
protein levels and activity of CUGBP1. J. Biol. Chem. 2001, 276: 
7820-6. 
[67]  Dansithong, W., Paul, S., Comai, L., Reddy, S. MBNL1 is the 
primary determinant of focus formation and aberrant insulin recep-
tor splicing in DM1. J. Biol. Chem. 2005, 280: 5773-80. 
[68]  Barreau, C., Paillard, L., Mereau, A., Osborne, H.B. Mammalian 
CELF/Bruno-like RNA-binding proteins: molecular characteristics 
and biological functions. Biochimie 2006, 88: 515-25. 
[69]  Kuyumcu-Martinez, N.M., Wang, G.S., Cooper, T.A. Increased 
steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to 
PKC-mediated hyperphosphorylation. Mol. Cell 2007, 28: 68-78. 
[70]  Timchenko, N.A., Patel, R., Iakova, P., Cai, Z.J., Quan, L., Tim-
chenko, L.T. Overexpression of CUG triplet repeat-binding protein, 
CUGBP1, in mice inhibits myogenesis. J. Biol. Chem. 2004, 279: 
13129-39. 
[71]  Philips, A.V., Timchenko, L.T., Cooper, T.A. Disruption of splic-
ing regulated by a CUG-binding protein in myotonic dystrophy. 
Science 1998, 280: 737-41. 
[72]  Mahadevan, M.S., Yadava, R.S., Yu, Q., Balijepalli, S., Frenzel-
McCardell, C.D., Bourne, T.D., Phillips, L.H. Reversible model of 
RNA toxicity and cardiac conduction defects in myotonic dystro-
phy. Nat. Genet. 2006, 38: 1066-70. 516    Current Genomics, 2008, Vol. 9, No. 8  Llamusí and Artero 
[73]  Kim, D.H., Langlois, M.A., Lee, K.B., Riggs, A.D., Puymirat, J., 
Rossi, J.J. HnRNP H inhibits nuclear export of mRNA containing 
expanded CUG repeats and a distal branch point sequence. Nucleic 
Acids Res. 2005, 33: 3866-74. 
[74]  Paul, S., Dansithong, W., Kim, D., Rossi, J., Webster, N.J., Comai, 
L., Reddy, S. Interaction of muscleblind, CUG-BP1 and hnRNP H 
proteins in DM1-associated aberrant IR splicing. EMBO J. 2006, 
25: 4271-83. 
[75]  Osborne, R.J., Thornton, C.A. RNA-dominant diseases. Hum. Mol. 
Genet. 2006, 15(Suppl 2): R162-9. 
[76]  Mankodi, A., Takahashi, M.P., Jiang, H., Beck, C.L., Bowers, 
W.J., Moxley, R.T., Cannon, S.C., Thornton, C.A. Expanded CUG 
repeats trigger aberrant splicing of ClC-1 chloride channel pre-
mRNA and hyperexcitability of skeletal muscle in myotonic dys-
trophy. Mol. Cell 2002, 10: 35-44. 
[77]  Lueck, J.D., Mankodi, A., Swanson, M.S., Thornton, C.A., Dirk-
sen, R.T. Muscle chloride channel dysfunction in two mouse mod-
els of myotonic dystrophy. J. Gen. Physiol. 2007, 129: 79-94. 
[78]  Berg, J., Jiang, H., Thornton, C.A., Cannon, S.C. Truncated ClC-1 
mRNA in myotonic dystrophy exerts a dominant-negative effect on 
the Cl current. Neurology 2004, 63: 2371-5. 
[79]  Ranum, L.P., Day, J.W. Myotonic dystrophy: RNA pathogenesis 
comes into focus. Am. J. Hum. Genet. 2004, 74: 793-804. 
[80]  Ishiura, S., Kino, Y., Nezu, Y., Onishi, H., Ohno, E., Sasagawa, N. 
Regulation of splicing by MBNL and CELF family of RNA-
binding protein. Acta Myol. 2005, 24: 74-7. 
[81]  Jasper, H., Benes, V., Atzberger, A., Sauer, S., Ansorge, W., 
Bohmann, D. A genomic switch at the transition from cell prolif-
eration to terminal differentiation in the Drosophila eye. Dev. Cell 
2002, 3: 511-21. 
[82]  Lin, X., Miller, J.W., Mankodi, A., Kanadia, R.N., Yuan, Y., Mox-
ley, R.T., Swanson, M.S., Thornton, C.A. Failure of MBNL1-
dependent postnatal splicing transitions in myotonic dystrophy. 
Hum. Mol. Genet. 2006, 15: 2087-97. 
[83]  Ladd, A.N., Charlet, N., Cooper, T.A. The CELF family of RNA 
binding proteins is implicated in cell-specific and developmentally 
regulated alternative splicing. Mol. Cell Biol. 2001, 21: 1285-96. 
[84]  Ho, T.H., Savkur, R.S., Poulos, M.G., Mancini, M.A., Swanson, 
M.S., Cooper, T.A. Colocalization of muscleblind with RNA foci is 
separable from mis-regulation of alternative splicing in myotonic 
dystrophy. J. Cell Sci. 2005, 118: 2923-33. 
[85]  Kino, Y., Mori, D., Oma, Y., Takeshita, Y., Sasagawa, N., Ishiura, 
S. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG 
repeats. Hum. Mol. Genet. 2004, 13: 495-507. 
[86]  Li, L.B., Yu, Z., Teng, X., Bonini, N.M. RNA toxicity is a compo-
nent of ataxin-3 degeneration in Drosophila. Nature 2008,  453: 
1107-11. 
[87]  Yuan, Y., Compton, S.A., Sobczak, K., Stenberg, M.G., Thornton, 
C.A., Griffith, J.D., Swanson, M.S. Muscleblind-like 1 interacts 
with RNA hairpins in splicing target and pathogenic RNAs. Nu-
cleic Acids Res. 2007, 35: 5474-86. 
[88]  Malinina, L. Possible involvement of the RNAi pathway in 
trinucleotide repeat expansion diseases. J .  Biomol. Struct. Dyn. 
2005, 23: 233-5. 
[89]  Robb, G.B., Brown, K.M., Khurana, J., Rana, T.M. Specific and 
potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol. 
2005, 12: 133-7. 
[90]  Krol, J., Fiszer, A., Mykowska, A., Sobczak, K., de Mezer, M., 
Krzyzosiak, W.J. Ribonuclease dicer cleaves triplet repeat hairpins 
into shorter repeats that silence specific targets. Mol. Cell 2007, 25: 
575-86. 
[91]  Salisbury, E., Sakai, K., Schoser, B., Huichalaf, C., Schneider-
Gold, C., Nguyen, H., Wang, G.L., Albrecht, J.H., Timchenko, L.T. 
Ectopic expression of cyclin D3 corrects differentiation of DM1 
myoblasts through activation of RNA CUG-binding protein, 
CUGBP1. Exp. Cell Res. 2008, 314: 2266-78. 
[92]  Iakova, P., Wang, G.L., Timchenko, L., Michalak, M., Pereira-
Smith, O.M., Smith, J.R., Timchenko, N.A. Competition of 
CUGBP1 and calreticulin for the regulation of p21 translation de-
termines cell fate. EMBO J. 2004, 23: 406-17. 
[93]  Karagiannides, I., Thomou, T., Tchkonia, T., Pirtskhalava, T., 
Kypreos, K.E., Cartwright, A., Dalagiorgou, G., Lash, T.L., 
Farmer, S.R., Timchenko, N.A. Increased CUG triplet repeat-
binding protein-1 predisposes to impaired adipogenesis with aging. 
J. Biol. Chem. 2006, 281: 23025-33. 
[94]  Nezu, Y., Kino, Y., Sasagawa, N., Nishino, I., Ishiura, S. Expres-
sion of MBNL and CELF mRNA transcripts in muscles with myo-
tonic dystrophy. Neuromuscul. Disord. 2007, 17: 306-12. 
[95]  Iwahashi, C.K., Yasui, D.H., An, H.J., Greco, C.M., Tassone, F., 
Nannen, K., Babineau, B., Lebrilla, C.B., Hagerman, R.J., Hager-
man, P.J. Protein composition of the intranuclear inclusions of 
FXTAS. Brain 2006, 129: 256-71. 
[96]  Rudnicki, D.D., Holmes, S.E., Lin, M.W., Thornton, C.A., Ross, 
C.A., Margolis, R.L. Huntington's disease--like 2 is associated with 
CUG repeat-containing RNA foci. Ann. Neurol. 2007, 61: 272-82. 
[97]  Gomes-Pereira, M., Monckton, D.G. Chemical modifiers of unsta-
ble expanded simple sequence repeats: what goes up, could come 
down. Mutat. Res. 2006, 598: 15-34. 
[98]  Seznec, H., Lia-Baldini, A.S., Duros, C., Fouquet, C., Lacroix, C., 
Hofmann-Radvanyi, H., Junien, C., Gourdon, G. Transgenic mice 
carrying large human genomic sequences with expanded CTG re-
peat mimic closely the DM CTG repeat intergenerational and so-
matic instability. Hum. Mol. Genet. 2000, 9: 1185-94. 
[99]  Denovan-Wright, E.M., Davidson, B.L. RNAi: a potential therapy 
for the dominantly inherited nucleotide repeat diseases. Gene Ther. 
2006, 13: 525-31.  
 
 
 
 
 